171
5
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T9706 | BTK inhibitor 17 | BTK | |
BTK inhibitor 17 is a potent irreversible BTK inhibitor (IC50 = 2.1 nM). BTK inhibitor 17 can be used in rheumatoid arthritis studies. | |||
T10629 | Btk inhibitor 2 | BGB-3111 analog | BTK |
Btk inhibitor 2 (BGB-3111 analog) is a BTK inhibitor. | |||
T35330 | BTK inhibitor 1 | BTK | |
BTK inhibitor 1 (Compound 27) is a BTK inhibitor (IC50: 0.11 nM) with an inhibitory effect on B-cell activation in hWB with an IC50 of 2 nM. | |||
TQ0230 | BTK IN-1 | SNS062 analog | BTK |
BTK IN-1 (SNS062 analog) (SNS062 analog) is an effective BTK inhibitor (IC50: <100 nM). | |||
T60542 | BTK-IN-16 | BTK | |
BTK-IN-16 is a potential inhibitor of wild-type BTK and C481S mutants.BTK-IN-16 can be used to study various autoimmune diseases and cancers caused by BTK. | |||
T40185 | BTK inhibitor 19 | ||
BTK inhibitor 19 is a highly selective, covalent BTK inhibitor ( IC 50 = 2.7 nM). | |||
T39612 | BTK-IN-5 | ||
BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases, respiratory diseases, inflammation, and diabetes. | |||
T9813 | JAK3/BTK-IN-2 | JAK , BTK | |
JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor. JAK3/ BTk-in-2 inhibits both BTK and JAK3, which are two important targets IN autoimmune diseases. JAK3/ BTk-in-2 simultaneously inhibits the BTK/JAK3 signaling pathway, sho... | |||
T9814 | JAK3/BTK-IN-1 | JAK , BTK | |
JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important targets in autoimmune diseases. JAK3/ BTk-in-1 simultaneously inh... | |||
T10628 | BTK inhibitor 13 | Others | |
BTK inhibitor 13 (compound 8) is an effective and selective BTK inhibitor(IC50: 1.2 nM). | |||
T36297 | Btk inhibitor 1 hydrochloride | ||
Btk inhibitor 1 Hcl is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor.IC50 value:Target: BtkFrom PCT Int. Appl. (2012), WO 2012158843 A2 20121122. [1]. PCT Int. Appl. (2012), WO 2012158843 A2 20121122. | |||
T14956 | CHMFL-BTK-01 | BTK | |
CHMFL-BTK-01 is an irreversible inhibitor of BTK (IC50: 7 nM) and also potently inhibits BTK Y223 auto-phosphorylation. | |||
T10627 | BTK inhibitor 10 | Others | |
BTK inhibitor 10 is a potent and orally active BTK inhibitor. It has the potential for rheumatoid arthritis treatment. | |||
T62716 | BTK-IN-10 | ||
BTK-IN-10 is a potent inhibitor of BTK, acting on wild-type BTK (IC50<5 nM) or mutant BTK (C481S) (IC50<5 nM). | |||
T75124 | BTK-IN-24 | ||
BTK-IN-24 (compound 195) is a potent BTK inhibitor via a ubiquitin proteolytic pathway [1] . | |||
T63810 | BTK-IN-7 | ||
BTK-IN-7 is a selective and potent BTK inhibitor with an IC50 value of 4.0 nM. BTK-IN-7 exhibits high selectivity at both the enzymatic (ITK>250-fold, EGFR>2500-fold) and cellular levels (ITK>227-fold, EGFR27-fold). BTK-... | |||
T63173 | BTK-IN-8 | ||
BTK-IN-8 is a potent, selective, peripheral covalent BTK inhibitor with an IC50 value of 0.22 nM and a Kd value of 0.91 nM. BTK-IN-8 exhibits good potency in whole blood CD69 cells with an IC50 value of 0.029 μM. | |||
T73276 | BTK-IN-23 | ||
BTK-IN-23 is a BTK inhibitor with an IC50 value of 12.8 nM, demonstrating kinase selectivity superior to Ibrutinib [1]. It also effectively inhibits BLX and BMX, with IC50 values of 35.6 nM and 5.7 nM, respectively. | |||
T72664 | BTK inhibitor 20 | ||
BTK inhibitor 20 is a potent BTK inhibitor with an IC 50 of 8 nM . | |||
T73275 | BTK-IN-22 | ||
BTK-IN-22, a BTK inhibitor (IC 50: 0.9 nM), also exhibits inhibition against BLX and BMX with IC 50 values of 1.4 and 1.2 nM, respectively. Demonstrating enhanced kinase selectivity, BTK-IN-22 outperforms Ibrutinib in th... | |||
T62472 | BTK-IN-6 | ||
BTK-IN-6 is a potent inhibitor of Bruton's tyrosine kinase (BTK). BTK-IN-6 has shown research potential in immune diseases, cardiovascular diseases, cancer, viral infections, inflammation, metabolic/endocrine dysfunction... | |||
T73319 | BTK-IN-19 | ||
BTK-IN-19 is a reversible BTK inhibitor with an IC 50 of <0.001 μM . | |||
T63182 | BTK-IN-15 | ||
BTK-IN-15 is a novel, orally active Bruton's tyrosine kinase (BTK) inhibitor that inhibits BTK (IC50: 0.7 nM). BTK-IN-15 induces apoptosis in cancer cells and has good kinase selectivity and anti-tumour activity. | |||
T79113 | BTK-IN-25 | BTK | |
BTK-IN-25 (compound 71) is a potent BTK inhibitor, demonstrating an IC50 of 0.77 nM against BTK(C481S) and achieving an IC50 of 1 nM in DOHH2 cells [1]. | |||
T73303 | BTK-IN-17 | ||
BTK-IN-17 is a selective, orally active inhibitor of Bruton's Tyrosine Kinase (BTK) with an inhibition concentration (IC50) value of 13.7 nM. It effectively reduces the expression of phosphorylated BTK at Tyrosine 223 (p... | |||
T63254 | BTK-IN-11 | ||
BTK-IN-11 is a potent inhibitor of BTK. BTK-IN-11 has shown potential for research in diseases related to autoimmune diseases, inflammatory diseases or cancer. | |||
T73318 | BTK-IN-18 | ||
BTK-IN-18 is a potent, reversible inhibitor of Bruton's tyrosine kinase (BTK) with an inhibitory concentration (IC50) of 0.002 µM. Additionally, it effectively suppresses CD69 and CD86 expression in vivo. | |||
T64042 | BTK inhibitor 18 | ||
BTK inhibitor 18 is a selective, potent, covalent, orally active Btk inhibitor (IC50: 142 nM) that exhibits anti-inflammatory effects. | |||
T63179 | BTK-IN-9 | ||
BTK-IN-9 is a reversible inhibitor of BTK that shows strong anti-proliferative effects in condyloma cells.BTK-IN-9 specifically disrupts mitochondrial membrane potential, increases reactive oxygen species levels in Z138 ... | |||
T79812 | BTK-IN-27 | BTK | |
BTK-IN-27 (example 8), a potent BTK inhibitor with an IC50 of 0.2 nM, demonstrates anti-proliferative effects in TMD8 cells with an IC50 of less than 5 nM. It is suitable for the research of various conditions including ... | |||
T78782 | PROTAC BTK Degrader-6 | BTK | |
PROTAC BTK Degrader-6 (Compound 15), with a DC50 of 3.18 nM, exhibits anti-inflammatory properties by inhibiting NF-κB activation and suppressing the expression of pro-inflammatory cytokines, such as IL-1β and IL-6 [1]. | |||
T74636 | PROTAC BTK Degrader-1 | ||
PROTAC BTK Degrader-1, a powerful, selective, and orally bioavailable degrader of PROTAC BTK, demonstrates effective reduction in BTK protein levels and tumor suppression. It exhibits IC50 values of 34.51 nM for BTK WT a... | |||
T62813 | JAK3/BTK-IN-6 | ||
JAK3/BTK-IN-6 is a potent dual inhibitor of BTK (IC50: 0.6 nM) and JAK3 (IC50: 0.4 nM).JAK3/BTK-IN-6 exhibits good metabolic stability in human liver microsomes.JAK3/BTK-IN-6 can be used to study blood and immune disease... | |||
T79067 | PROTAC BTK Degrader-3 | PROTACs | |
PROTAC BTK Degrader-3 is a potent degrader of Bruton's tyrosine kinase (BTK), exhibiting a DC50 (median degradation concentration) of 10.9 nM in Mino cells. This compound shows promise for research into B-cell malignanci... | |||
T79292 | PROTAC BTK Degrader-5 | BTK | |
PROTAC BTK Degraders-5 (Compound 3e) is a selective Bruton's tyrosine kinase (BTK) degrader with a DC50 of 7.0 nM in JeKo-1 cells, demonstrating specificity by not affecting CRBN neosubstrates. It also exhibits antiproli... | |||
T62234 | JAK3/BTK-IN-3 | ||
JAK3/BTK-IN-3 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets in autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway has a synergistic effect and JAK3/BTK-IN-3 has sh... | |||
T62153 | JAK3/BTK-IN-5 | ||
JAK3/BTK-IN-5 is a potent inhibitor of JAK3/BTK. where BTK and JAK3 are two key targets in autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway has a synergistic effect and JAK3/BTK-IN-5 has po... | |||
T62553 | JAK3/BTK-IN-4 | ||
JAK3/BTK-IN-4 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets in autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signaling pathway has a synergistic effect and JAK3/BTK-IN-4 has pot... | |||
T73868 | PROTAC BTK Degrader-2 | ||
PROTAC BTK Degrader-2, a potent degrader of BTK through the PROTAC mechanism, effectively diminishes BTK protein levels [1]. | |||
T16730 | Remibrutinib | BTK | |
Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood. Remibrutinib is an effective and orally active Bruton tyrosine kinase inhibitor (IC50: 1 nM). Remibrutinib has the potential for Chronic urticar... | |||
T1976 | RN486 | BTK | |
RN486 is an effective and specific BTK inhibitor (IC50: 4 nM). | |||
T5138 | BMS-986142 | BTK | |
BMS-986142 is a potent and highly selective reversible BTK inhibitor (IC50: 0.5 nM). | |||
T16157 | MT-802 | BTK , PROTACs | |
MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL). | |||
T36287 | Pirtobrutinib | BTK | |
Pirtobrutinib (LOXO-305) is an advanced BTK inhibitor that displays high selectivity and operates through a non-covalent mechanism. This compound effectively inhibits various BTK C481 substitution mutations, leading to t... | |||
T10625 | IBT6A | BTK | |
IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. | |||
T10626 | (Rac)-IBT6A | Others , BTK | |
(Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib and can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. | |||
T2472 | CGI-1746 | BTK , Autophagy | |
CGI1746 is a potent and highly selective small-molecule Btk inhibitor with IC50 of 1.9 nM. | |||
TQ0242 | Fenebrutinib | GDC-0853 | BTK |
Fenebrutinib (GDC-0853) is a selective and noncovalent Btk inhibitor (Ki: 0.91 nM). | |||
T5407 | Branebrutinib | BMS986195 | BTK |
Branebrutinib (BMS986195) is a potent, covalent inhibitor of Bruton's tyrosine kinase (BTK), >5,000-fold selective over all kinases outside of the Tec family (IC50 <1 nM for BTK). | |||
T12542 | Rilzabrutinib | PRN1008 | EGFR , Others , HER , BTK |
Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM). |
Cat No. | Product Name | Species | Expression System |
---|---|---|---|
TMPH-02271 | BTK Protein, Human, Recombinant (His) | Human | Baculovirus |
Key element of the urea cycle converting L-arginine to urea and L-ornithine, which is further metabolized into metabolites proline and polyamides that drive collagen synthesis and bioenergetic pathways critical for cell ... | |||
TMPH-02037 | Human rhinovirus 1B (HRV-1B) Genome polyprotein (His & Myc) | HRV-1B | E. coli |
Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activatio... | |||
TMPY-05249 | ITK Protein, Human, Recombinant (Actived By LCK, GST) | Human | Baculovirus-Insect Cells |
IL-2-inducible T cell kinase is a member of the protein kinase superfamily, Tyr protein kinase family, and TEC subfamily. It contains 1 Btk-type zinc finger, 1 PH domain, 1 protein kinase domain, 1 SH2 domain, and 1 SH3 ... | |||
TMPY-04570 | ITK Protein, Mouse, Recombinant (aa 351-619, His & GST) | Mouse | Baculovirus-Insect Cells |
IL-2-inducible T cell kinase is a member of the protein kinase superfamily, Tyr protein kinase family, and TEC subfamily. It contains 1 Btk-type zinc finger, 1 PH domain, 1 protein kinase domain, 1 SH2 domain, and 1 SH3 ... | |||
TMPH-02664 | Aldolase C Protein, Mouse, Recombinant (His) | Mouse | Yeast |
Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors and plays an important role in the regulation of innate and adaptive immune responses, hematopoiesis, responses to growth factors an... |